BRAVIFO INJECTION

Indications

• Breast cancer
• Ovarian cancer
• Non-small cell lung cancer
• Kaposi's sarcoma
• Gastrointestinal cancers

Dosage

Children: Refer to official pediatric dosing guidelines.

Adults: Refer to official prescribing information for specific dosing guidelines.

Mechanism of action

Paclitaxel binds to the beta subunit of tubulin, promoting the assembly of microtubules and stabilizing them against depolymerization. This leads to the prevention of mitotic spindle formation, effectively halting the cell cycle in the G2/M phase and resulting in apoptosis of cancer cells.

Pharmacodynamics

The pharmacodynamics of paclitaxel involve its ability to inhibit cell division by stabilizing microtubules, which are critical for mitosis. This action results in a decrease in cancer cell proliferation and can lead to cell death, particularly in rapidly dividing cells. The drug's effects are not limited to cancer cells and may also impact normal cells that divide quickly.

Pharmacokinetics

Paclitaxel is administered intravenously and exhibits a high protein binding rate, primarily to albumin and alpha-1 acid glycoprotein. The drug is metabolized in the liver by cytochrome P450 enzymes, particularly CYP2C8 and CYP3A4. Its elimination half-life varies, but it is generally in the range of 11 to 50 hours, depending on the formulation and patient factors. Paclitaxel is excreted mainly in the feces, with a smaller amount eliminated via urine.

Contra-indications

• Hypersensitivity to paclitaxel or any component of the formulation
• Severe neutropenia
• Pregnancy

Adverse effects

• Myelosuppression
• Peripheral neuropathy
• Alopecia
• Nausea and vomiting
• Hypersensitivity reactions
• Cardiotoxicity
• Mucositis
• Fatigue

Interactions

• CYP2C8 and CYP3A4 inhibitors may increase paclitaxel plasma concentrations
• CYP2C8 and CYP3A4 inducers may decrease paclitaxel plasma concentrations
• Concurrent use with other myelosuppressive agents may enhance the risk of hematologic toxicity

Precautions

• Monitor complete blood counts regularly during treatment
• Use caution in patients with hepatic impairment
• Avoid use in patients with a history of allergic reactions to taxanes
• Assess for signs of infection due to potential myelosuppression

Pregnancy

Paclitaxel is classified as a Category D drug. It may cause harm to the fetus and is not recommended during pregnancy.

Breast-feeding

It is not known whether paclitaxel is excreted in human milk. Caution should be exercised when administered to nursing women.

Storage

Store at room temperature, protected from light. Do not freeze. Reconstituted solutions should be used immediately or stored under refrigeration for a limited time.

Formulations

• Injectable solution (concentrate for solution for infusion)
• Intravenous infusion